{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:44:38Z","timestamp":1790109878149,"version":"4.0.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Myeloma survival has greatly increased over past decades. We investigated trends in survival over time in New Zealand by age, ethnicity, and geography and thus examined potential inequalities among these population subgroups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>From data supplied by the New Zealand Ministry of Health, all new diagnoses of multiple myeloma (ICD-10 code C90) between 1990 and 2016 were extracted, as well as their matched mortality data. Cox\u2019s proportional hazards regression and competing risks regression were used to estimate multivariable survival functions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between 1 January 1990 and 1 December 2015, 6642 myeloma cases were registered by the New Zealand Cancer Registry. Although survival from myeloma increased substantially from 1990\u20131994 to 2010\u20132015, 5-year survival was still only about 60% in 2010\u20132015. The greatest improvement in survival was for people aged 60\u201369\u2009years at diagnosis. Using Cox\u2019s proportional hazards regression, M\u0101ori showed an increased risk of myeloma death but this was predominantly due to differences in competing risks among ethnic groups. Competing risks analysis found the greatest improvement in myeloma survival in Pacific Islanders, and in 2010\u20132015 M\u0101ori had better survival than other ethnicities. Myeloma survival improved significantly over time in all regional health authorities but in all time periods the Central and Southern regions had significantly poorer survival than the Midland region.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Improvements in myeloma survival have been unequal across subgroups and regions in New Zealand. Detailed information about utilization of chemotherapeutic agents and transplantation in New Zealand is not available. This information, as well as more detailed hematological data, is essential to further explore the relationships and reasons for differing myeloma survival in population subgroups of New Zealand.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12885-021-08544-7","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T11:02:54Z","timestamp":1626433374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Trends in survival from myeloma, 1990\u20132015: a competing risks analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Mary Jane","family":"Sneyd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Morison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,16]]},"reference":[{"issue":"9","key":"8544_CR1","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.3109\/10428194.2014.1003060","volume":"56","author":"E Samy","year":"2015","unstructured":"Samy E, Ross J, Bolton E, Morris E, Oliver S. Variation in incidence and survival by ethnicity for patients with myeloma in England (2002-2008). Leuk Lymphoma. 2015;56(9):2660\u20137. https:\/\/doi.org\/10.3109\/10428194.2014.1003060.","journal-title":"Leuk Lymphoma"},{"key":"8544_CR2","unstructured":"GLOBOCAN 2012 v1.0. Cancer incidence and mortality worldwide: IARC; 2013. [cited 29\/10\/14]. Available from: http:\/\/globocan.iarc.fr"},{"key":"8544_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.canep.2019.03.006","volume":"60","author":"M Sneyd","year":"2019","unstructured":"Sneyd M, Cox B, Morison I. Trends in myeloma incidence, mortality and survival in New Zealand (1985-2016). Cancer Epidemiol. 2019;60:55\u20139. https:\/\/doi.org\/10.1016\/j.canep.2019.03.006.","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"8544_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1471-2407-10-74","volume":"10","author":"C Renshaw","year":"2010","unstructured":"Renshaw C, Ketley N, Moller H, Davies E. Trends in the incidence and survival of multiple myeloma in south East England 1985-2004. BMC Cancer. 2010;10(1):74\u201381. https:\/\/doi.org\/10.1186\/1471-2407-10-74.","journal-title":"BMC Cancer"},{"issue":"S1","key":"8544_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/sj.bjc.6604607","volume":"99","author":"B Rachet","year":"2008","unstructured":"Rachet B, Mitry E, Shah A, Cooper N, Coleman M. Survival from multiple myeloma in England and Wales up to 2001. Br J Cancer. 2008;99(S1):110\u20132.","journal-title":"Br J Cancer"},{"issue":"5","key":"8544_CR6","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.3109\/10428194.2013.827188","volume":"55","author":"D Pulte","year":"2014","unstructured":"Pulte D, Redaniel M, Brenner H, Jansen L, Jeffreys M. Recent improvement in survival of patients with multiple myeloma: variation by ethnicity. Leuk Lymphoma. 2014;55(5):1083\u20139. https:\/\/doi.org\/10.3109\/10428194.2013.827188.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"8544_CR7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/leu.2011.368","volume":"26","author":"A Greenberg","year":"2012","unstructured":"Greenberg A, Vachon C, Rajkumar S. Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia. 2012;26(4):609\u201314. https:\/\/doi.org\/10.1038\/leu.2011.368.","journal-title":"Leukemia."},{"issue":"5","key":"8544_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/ajh.21139","volume":"83","author":"P Verma","year":"2008","unstructured":"Verma P, Howard R, Weiss B. The impact of race on outcomes of autologous transplantation in patients with multiple myeloma. Am J Hematol. 2008;83(5):355\u20138. https:\/\/doi.org\/10.1002\/ajh.21139.","journal-title":"Am J Hematol"},{"issue":"3","key":"8544_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.bbmt.2009.11.007","volume":"16","author":"P Hari","year":"2010","unstructured":"Hari P, Majhail N, Zhang M-J, Hassebroek A, Siddiqui F, Ballen A, et al. Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2010;16(3):395\u2013402. https:\/\/doi.org\/10.1016\/j.bbmt.2009.11.007.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"8544_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau J-L, Stoppa A-M, Sotto J-J, Fuzibet J-G, Rossi J-F, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335(2):91\u20137. https:\/\/doi.org\/10.1056\/NEJM199607113350204.","journal-title":"N Engl J Med"},{"issue":"4","key":"8544_CR11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1517\/14712598.2016.1136285","volume":"16","author":"M Martino","year":"2016","unstructured":"Martino M, Recchia A, Fedele R, Neri S, Vincelli I, Moscato T, et al. The role of tandem stem cell transplantation for multiple myeloma patients. Expert Opin Biol Ther. 2016;16(4):515\u201334. https:\/\/doi.org\/10.1517\/14712598.2016.1136285.","journal-title":"Expert Opin Biol Ther"},{"key":"8544_CR12","unstructured":"Ministry of Health. Mortality data and stats. Wellington, New Zealand; 2014. updated June, 2014."},{"issue":"3","key":"8544_CR13","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3324\/haematol.2017.178103","volume":"103","author":"C Blimark","year":"2018","unstructured":"Blimark C, Turesson I, Genell A, Ahlberg L, Bj\u00f6rkstrand B, Carlson K, et al. Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish myeloma registry. Haematologica. 2018;103(3):506\u201313. https:\/\/doi.org\/10.3324\/haematol.2017.178103.","journal-title":"Haematologica."},{"key":"8544_CR14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/978-3-642-55345-5_5","volume-title":"Developments in Statistical Evaluation of Clinical Trials","author":"K van Montfort","year":"2014","unstructured":"van Montfort K, Fennema P, Ghidey W. Competing risks and survival analysis. In: Van Montfort KOJ, Ghidey W, editors. Developments in Statistical Evaluation of Clinical Trials. Berlin: Springer-Verlag; 2014. p. 85\u201396."},{"issue":"2","key":"8544_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1158\/1078-0432.CCR-06-1210","volume":"13","author":"H Kim","year":"2007","unstructured":"Kim H. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res. 2007;13(2):559\u201365. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1210.","journal-title":"Clin Cancer Res"},{"issue":"446","key":"8544_CR16","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"J Fine","year":"1999","unstructured":"Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496\u2013509. https:\/\/doi.org\/10.1080\/01621459.1999.10474144.","journal-title":"J Am Stat Assoc"},{"key":"8544_CR17","volume-title":"Ethnic groups in New Zealand","author":"Statistics New Zealand","year":"2014","unstructured":"Statistics New Zealand. Ethnic groups in New Zealand. Wellington, New Zealand: Statistics New Zealans; 2014."},{"issue":"5","key":"8544_CR18","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.canep.2015.08.002","volume":"39","author":"R R\u00edos-Tamayo","year":"2015","unstructured":"R\u00edos-Tamayo R, S\u00e1nchez M, Puerta J, S\u00e1inz J, Chang D, Rodr\u00edguez T, et al. Trends in survival of multiple myeloma: a thirty-year population-based study in a single institution. Cancer Epidemiol. 2015;39(5):693\u20139. https:\/\/doi.org\/10.1016\/j.canep.2015.08.002.","journal-title":"Cancer Epidemiol"},{"key":"8544_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.canep.2018.01.015","volume":"53","author":"M Andres","year":"2018","unstructured":"Andres M, Feller A, Arndt V. The NICER working group. Trends of incidence, mortality, and survival of multiple myeloma in Switzerland between 1994 and 2013. Cancer Epidemiol. 2018;53:105\u201310. https:\/\/doi.org\/10.1016\/j.canep.2018.01.015.","journal-title":"Cancer Epidemiol"},{"issue":"11","key":"8544_CR20","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1634\/theoncologist.2011-0229","volume":"16","author":"D Pulte","year":"2011","unstructured":"Pulte D, Gondos A, Brenner H. Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. Oncologist. 2011;16(11):1600\u20133. https:\/\/doi.org\/10.1634\/theoncologist.2011-0229.","journal-title":"Oncologist"},{"issue":"5","key":"8544_CR21","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","volume":"111","author":"H Brenner","year":"2008","unstructured":"Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111(5):2521\u20136. https:\/\/doi.org\/10.1182\/blood-2007-08-104984.","journal-title":"Blood."},{"issue":"8","key":"8544_CR22","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1182\/blood-2007-03-081018","volume":"111","author":"H Ludwig","year":"2008","unstructured":"Ludwig H, Durie B, Bolejack V, Turesson I, Kyle R, Blade J, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10549 patients from the international myeloma working group. Blood. 2008;111(8):4039\u201347. https:\/\/doi.org\/10.1182\/blood-2007-03-081018.","journal-title":"Blood."},{"issue":"5","key":"8544_CR23","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"S Kumar","year":"2014","unstructured":"Kumar S, Dispenzieri A, Lacy M, Gertz M, Buadi F, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122\u20138. https:\/\/doi.org\/10.1038\/leu.2013.313.","journal-title":"Leukemia."},{"issue":"1","key":"8544_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ejca.2009.07.006","volume":"46","author":"M Schaapveld","year":"2010","unstructured":"Schaapveld M, Visser O, Siesling S, Schaar C, Zweegman S, Vellenga E. Improved survival among younger but not among older patients with multiple myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer. 2010;46(1):160\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2009.07.006.","journal-title":"Eur J Cancer"},{"issue":"2","key":"8544_CR25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1182\/bloodadvances.2017010512","volume":"2","author":"D Pulte","year":"2018","unstructured":"Pulte D, Nie L, Gormley N, Goldberg K, McKee A, Farrell A, et al. Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications. Blood Adv. 2018;2(2):116\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2017010512.","journal-title":"Blood Adv"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08544-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08544-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08544-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T04:22:33Z","timestamp":1699244553000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08544-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,16]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8544"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08544-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,16]]},"assertion":[{"value":"11 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data used in this study were collected by the New Zealand Ministry of Health under the Cancer Registry Act, 1993 and pursuant regulations (1994). Under this act, notification of all cancers (excluding non-melanoma skin cancers) is required by law and individual consent is not sought. The Cancer Registry Act 1993 states that the purposes of the New Zealand Cancer Registry are:a. to provide information on the incidence of, and mortality from, cancerb. to provide a basis for cancer survival studies and research programmes.The New Zealand Ministry of Health provides raw data to the Hugh Adam Cancer Epidemiology Unit of the University of Otago with the approval of the Health and Disability Ethics Committees MEC\/09\/65\/EXP\/AM06.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"821"}}